CTOs on the Move

Seattle Genetics

www.seattlegenetics.com

 
Targeting Cancer. Transforming Therapies. Revolutionary science meets transformative cancer therapy Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Suresh Namala
Executive Director, IT Risk and Compliance Profile

Funding

Seattle Genetics raised $1B on 09/14/2020

Similar Companies

Fortis Life Sciences

Fortis Life Sciences offers word-class reagents, tools, materials, and custom services for our research, diagnostic and therapeutic customers. Learn more here.

STEMCELL Technologies

STEMCELL Technologies is a biotechnology company that develops specialty cell culture media and cell separation products to support research in the fields of immunology, hematology, neuroscience, mesenchymal cell, stem cell and epithelial cell biology. We also provide instruments, cytokines, antibodies, training courses, proficiency testing and contract assay services. Driven by science and a passion for quality, STEMCELL delivers over 2500 products to more than 80 countries worldwide. STEMCELL Technologies provides consistent, unfailing quality and one-on-one assistance to help you succeed. We do this because we love science as much as you do.

GrayBug

GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.

LightDeck Diagnostics

MBio Diagnostics is now LightDeck Diagnostics! LightDeck Diagnostics believes in a new approach to healthcare, where fast, accurate, simple, low-cost diagnostic tests will be run wherever and whenever they are needed, without compromise. The company`s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented manufacturing techniques to deliver lab-quality results anywhere, in minutes. LightDeck is introducing a portfolio of in vitro diagnostic panels, the first is an on-the-spot test for COVID-19. The LightDeck platform is currently commercialized in veterinary diagnostics and for environmental testing. Learn more at www.LightDeckDx.com Platform Technology The LightDeck platform consists of a robust, portable fluorescence analyzer and disposable, multiplex test cartridges. The LightDeck® platform was designed to meet customer requirements: • Quality: Highly sensitive tests that deliver lab-quality results • Quick: Actionable data in as little as 5 minutes with a simple procedure • Quantitative: More data to inform treatment decisions • Multiplex: Multiple related tests for better precision plus internal quality control to maximize safety The test procedure is simple enough that an untrained user can perform testing almost anywhere. Panels can be configured to run multiple related tests simultaneously to help diagnosis or rule-out a specific condition. Internal quality control runs with every test to ensure quality and not report questionable results.

Alumis

We are a precision medicines company looking to eliminate the “all comer” approach that is seen with today`s treatments for people with autoimmune disease. We are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.